ALSO READ | Centre Announces Rs 23,123 Cr Mega Covid Response Package, Provision for Pediatric Care, 20K ICU Beds
“Covaxin phase 3 trials have started and by the end of September, I think we should be there (begin vaccination). I think sometime in the third quarter or by early January-February we should be able to give it to 2 to 18-year-olds,” Dr Arora said.
A new study has found that a single shot of Pfizer-BioNTech or AstraZeneca vaccines for Covid-19 “barely” work against the Delta variant of the deadly virus. The study, published in the journal Nature, revealed that fully vaccinated individuals of Pfizer-BioNtech or AstraZeneca vaccine are well protected.
Amid the spread of the highly contagious Delta variant, Pfizer plans to seek US regulators nod for third COVID19 vaccine dose within the next month. It said that it could boost protection against delta variant. Its research suggested antibody levels jump markedly after a third dose, but it’s not yet clear if and when boosters might truly be needed, the drug-manufacturing company said.
The U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said, however, in a joint statement that Americans who have been fully vaccinated do not need a booster COVID-19 shot at this time.
Pfizer’s chief scientific officer, Mikael Dolsten, said the recently reported dip in the vaccine’s effectiveness in Israel was mostly due to infections in people who had been vaccinated in January or February. The country’s health ministry said vaccine effectiveness in preventing both infection and symptomatic disease fell to 64% in June.
Pfizer’s own data from the United States showed an erosion of the vaccine’s efficacy to the mid-80s after six months, Dolsten said, against the variants circulating there in the spring.
WHO Chief Scientist Dr Soumya Swaminathan on Thursday said data on Bharat Biotech’s vaccine Covaxin looks good. As Covaxin awaits WHO approval, Swaminathan said the pre-submission meeting was held on June 23 and the data packet is being assembled. The Phase-3 trial data looks good, they’ve looked at the variants too, she said in an interview to CNBC-TV18. “The overall efficacy is quite high. The vaccine efficacy against the Delta variant is low but it is still quite good,” she said. The safety profile so far meets the WHO benchmarks, the scientist said.
“We keep a close eye on all vaccines which have received emergency use listing. We continue to seek more data,” she said.
Uttarakhand has reported its first case of Delta Plus mutant of COVID19 with one person having tested positive for the variant in Udham Singh Nagar district. The person who tested positive for the variant has already returned to Lucknow from where he had come to Dineshpur in the district to his uncle’s place, Additional Chief Medical Officer of Udham Singh Nagar Avinash Khanna said.